FundedIQ
Biotechnology

Biomatter

Biomatter is a company specializing in synthetic biology that creates new proteins for medical and sustainable manufacturing purposes. The company has pioneered the Intelligent Architecture platform, which aims to overcome the constraints of current engineering methods and pave the way for innovative protein design and development.

www.biomatter.ai Vilnius, Lithuania 11-50 employees
Total raised
$7.1M
Rounds
1
Latest
Seed
Aug 2024

Biomatter is a company specializing in synthetic biology that creates new proteins for medical and sustainable manufacturing purposes. The company has pioneered the Intelligent Architecture platform, which aims to overcome the constraints of current engineering methods and pave the way for innovative protein design and development.

Biomatter has raised $7.1M across 1 round. Its most recent round was a Seed of $7.1M in Aug 2024. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Aug 5, 2024
Seed
$7.1M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Biomatter is featured in

Similar companies

Atrandi Biosciences

Atrandi Biosciences is a privately owned biotechnology company that specializes in advanced single-cell technology, with a focus on eukaryotic DNA sequencing at the single-cell level. This unique method enables the examination of genetic changes and variations in individual cells.

Series A $25.0M
Biohifas

Biohifas employs the power of mycelium and valorizes industrial side streams into the food. We are developing technology in 3 areas: - Side stream processing into food grade substrates. - Mycelium cultivation in solid state fermentation. - Raw material conservation. We are looking for curious minds, who are amazed by the great kingdom of fungi. Let's employ the power of mycelium and solve the problems that our world faces!

Series Unknown $30k
immunitoAI

ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics.

Series A $6.1M
AI Metrics

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum

Venture - Series Unknown $950k
Luminate Medical

Luminate Medical develops a medical device designed to prevent hair loss during chemotherapy. Luminate Medical recognises that hair is an essential element of personality and self-esteem, and is dedicated to using the latest advances in medical technology to protect this.

Venture - Series Unknown $17.0M
Hermes Biosciences

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

Seed $6.0M
InvenireX

InvenireX is a biotech company that provides molecular diagnostics services.

Seed $2.6M
Chromologics

Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.

Venture - Series Unknown $8.1M
Artios Pharma

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Series D $115M
Bambusa Therapeutics

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.

Series A
Proteine Resources

We're on a mission to revolutionize the use of insects, maximizing their potential in various industries. Our flagship product is a premium insect protein boasting 64% protein content in dry mass. What sets it apart are its remarkable medical properties, including unique amino and fatty acid profiles, as well as a rich array of vitamins and macro- and micronutrients. Even more impressive is its production efficiency — it can be produced 50% cheaper and at a larger scale, far outpacing any competition in the market. Our product range caters to the poultry feed, pet food, and veterinary supplement industries. These products are integral components of animal feeds, significantly reducing mortality rates, enhancing health, appearance, and overall well-being. Now, imagine the possibilities if we harness the bioactive compounds found in insects such as serotonin, melatonin, ecdysone, lovastatin, GABA, phenolic compounds, cordycepin, erinacenes, hericenones, psilocybin, psilocin, beta-glucan, and triterpenes. With these potent ingredients, we can develop high-value cosmetics and medicines tailored for specific therapeutic purposes, boasting exceptional bioavailability. This is the future of innovation in healthcare and beauty.

Venture - Series Unknown
Solarea Bio

Solarea Bio is a biotech company focused on developing microbial therapeutics to treat chronic inflammatory conditions and improve human health. They specialize in researching and creating natural-based therapeutics to address chronic inflammation, providing hospitals with effective medicinal options. By studying genomic sequences of microbes found in healthy foods, Solarea is able to create combinations of bacteria, fungi, and prebiotic fibers that have strong anti-inflammatory properties to target specific chronic illnesses. Their research has been tested in lab and animal studies, with their first application designed to help manage metabolic processes that lead to osteopenia and osteoporosis in postmenopausal women. Founded in 2017 in Cambridge, Massachusetts by Eric Schott, Gerardo Toledo, and Jillian DeWalt, Solarea Bio offers a natural solution to improve women's health and well-being.

Venture - Series Unknown $9.9M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.